Mesoblast downgraded by Piper Sandler with a new price target

8/4/23 7:34:48 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Piper Sandler downgraded Mesoblast from Overweight to Neutral and set a new price target of $2.00 from $7.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MESO

Date	Price Target	Rating	Analyst
12/23/2024		Buy → Hold	Jefferies
9/24/2024	$12.00	Hold → Buy	Maxim Group
8/29/2024		Hold → Buy	Jefferies
7/23/2024	$4.00 → $11.00	Neutral → Overweight	Piper Sandler
8/31/2023		Hold → Buy	Jefferies
8/7/2023		Buy → Hold	Maxim Group
8/4/2023	$7.00 → $2.00	Overweight → Neutral	Piper Sandler
8/4/2023		Outperform → Mkt Perform	William Blair